• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Switching directly to biologic therapy when methotrexate fails is not cost effective for treating rheumatoid arthritis

byAndrew Cheung, MD MBA
May 31, 2017
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Biologic therapy had minimal additional benefits for patients compared to triple therapy.

2. When used as a first-line therapy, triple therapy resulted in significantly lower drug costs than biologic therapy.

Evidence Rating Level: 2 (Good)

Study Rundown: Guidelines currently recommend treating rheumatoid arthritis patients with biologic drugs, such as etanercept, following failure of conventional disease modifying anti-rheumatic drugs (DMARDs). However, biologic drugs are highly expensive. Recent studies have suggested that an alternate therapy, known as DMARD triple therapy (sulfasalazine, hydroxychloroquine, and methotrexate), is equally as effective as adding a biologic to methotrexate. Considering these results, the goal of this study was to determine the cost-effectiveness of etancercept-methotrexate, compared to triple therapy, as a first-line strategy for rheumatoid arthritis. Generally, the authors observed that initiating biologic therapy, without trying triple therapy, increases costs without significant benefit. There are several limitations to this study. First, there is limited data regarding the long-term benefits of triple therapy. Second, the model used to assess cost did not account for the possibility of certain adverse effects, which may differ between the 2 different therapies. Overall, the results of this study suggest that triple therapy is an important first-line therapy to initiate prior to switching to biologics.

Click to read the study, published in the Annals of Internal Medicine

Relevant Reading: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

In-Depth [retrospective cohort]: The authors conducted a within-trial analysis based on the 353 participants of the Rheumatoid Arthritis Comparison of Active Therapies (RACAT) trial. They also performed a lifetime analysis, allowing them to extrapolate costs and outcomes by using a decision analytic cohort model. The outcomes assessed in this trial included incremental costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). Following the within-trial analysis, it was observed that etanercept-methotrexate, as a first-line treatment, only resulted in marginally more QALYs. In contrast, etanercept-methotrexate had significantly higher drug costs compared to triple therapy. Additionally, the lifetime analysis indicated that first-line etanercept-methotrexate would cost $77 290, at the expense of only a 0.15 additional lifetime QALY.

RELATED REPORTS

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: rheumatoid arthritis
Previous Post

No link between cesarean delivery and BMI in later childhood

Next Post

2 Minute Medicine Rewind May 29, 2017

RelatedReports

2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

August 3, 2022
2 Minute Medicine Rewind January 28, 2019
Cardiology

Tofacitinib increases cardiovascular and cancer risk in rheumatoid arthritis

February 2, 2022
#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection
StudyGraphics

#VisualAbstract: Immune dysfunction is associated with a higher risk of breakthrough COVID-19 infection

January 5, 2022
#VisualAbstract Granuloma annulare was associated with increased risk of type 2 diabetes, hyperlipidemia, and certain autoimmune conditions
Chronic Disease

#VisualAbstract Granuloma annulare was associated with increased risk of type 2 diabetes, hyperlipidemia, and certain autoimmune conditions

June 18, 2021
Next Post
ACP releases practice guidelines for the evaluation of suspected acute pulmonary embolism

2 Minute Medicine Rewind May 29, 2017

Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis

New prevalence estimates for hidradenitis suppurativa in the United States

Cardiac biomarkers unnecessarily ordered in emergency departments

Variation in markup of charges in emergency department and internal medicine services

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PI-RADS version 2: Standardized acquisition, interpretation, and reporting of prostate MRI [Classics Series]
  • #VisualAbstract: Capivasertib in addition to fulvestrant improves progression-free survival in ER⁺ advanced breast cancer
  • Tiotropium bromide safe and effective in treating early childhood wheezing
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.